Liver-Focused drug study for rare Light-Sensitivity disease halted before start
NCT ID NCT07123363
First seen Oct 31, 2025 · Last updated May 19, 2026 · Updated 30 times
Summary
This study was designed to see if bitopertin is safe and can lower harmful protoporphyrin IX levels in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) who also have early signs of liver damage. It was withdrawn before enrolling any participants, so no results are available. The goal was to manage the disease and protect the liver, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROTOPORPHYRIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.